基本信息
views: 35
![](https://originalfileserver.aminer.cn/sys/aminer/icon/show-trajectory.png)
Bio
Highly dedicated and creative scientist, my ambition is to make breakthrough in deciphering how to circumvent glioma mediated local and systemic immunosuppression and to translate our discoveries into more effective immunotherapeutic strategy to support patients’ outcomes.
In 2005, after obtaining my Master’s Degree in Biotechnology, I started as a research engineer in Dr. J. Zimmer group at the CRP-Santé, Luxembourg, the predecessor to the Luxembourg Institute of Health, Luxembourg (LIH). The research group interest focused on the biology of Natural Killer (NK) cells in both the context of TAP deficiency and their regulation by neurotrophic factors. I developed a strong background in immunology with a specialization in NK cell biology. In addition, through my active collaboration with multiple investigators, I extended my competences to the fields of Allergology, Oncology and Neuro-Immunology. During this period as engineer, I developed a strong expertise in the functional and phenotypic assessment of primary immune cells from mouse, rat and human, especially for NK cells and myeloid cells; with a demonstrated expertise in using multi-colour flow cytometry and ex vivo co-culture systems. In 2010, I undertook a PhD thesis at the doctoral school of the University of Bergen in Norway, under the supervision of Prof. M. Chekenya, working on the development of a new immunotherapeutic strategy in rodent models for its future translation into the treatment of glioblastoma (GBM) patients. These studies enabled me to acquire a strong background in the field of neuro-immunology as well as in brain tumour immunology. Since 2015, I have been working on implementing AllergoOncology research at LIH, with the support of both Prof. M. Ollert, Director of the Department of Infection and Immunity (DII), and Prof S. Niclou, Director of the Department of Cancer research (DoCR) at LIH. My research focuses on the understanding of the epidemiological association between glioma development and a pre-existing history of allergy. Since February 2021, I was strategically repositioned from DII to the DoCR by integrating the Neuro-Immunology Group headed by Dr Alessandro Michelucci to conduct and support new as well as ongoing immune-related projects aimed at exploring and exploiting molecular pathways to promote and restore anti-tumoral features of myeloid cells in the context of GBM.
I am elected board member of the Working Group for AllergoOncology, from the European Academy of Allergy and Clinical Immunology (EAACI). Furthermore, since 2022, I am chairing a newly created international Task Force of the working group for AllergoOncology; sponsored by the EAACI, on the topic of : “AllergoOncology in the Era of Personalized, Stratified and Precision Medicine”.
Research Interests
Papers共 47 篇Author StatisticsCo-AuthorSimilar Experts
By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Journal of Neuroinflammationno. 1 (2024): 1-24
biorxiv(2024)
Michelle C. Turner,Urszula Radzikowska,Denisa E. Ferastraoaru,Mariona Pascal,Pieter Wesseling, Alexandra Mccraw, Claudine Backes,Heather J. Bax,Christoph Bergmann,Rodolfo Bianchini,Luigi Cari,Leticia de las Vecillas,
ALLERGYno. 6 (2024): 1419-1439
Load More
Author Statistics
#Papers: 49
#Citation: 2832
H-Index: 20
G-Index: 49
Sociability: 6
Diversity: 0
Activity: 1
Co-Author
Co-Institution
D-Core
- 合作者
- 学生
- 导师
Data Disclaimer
The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn